EyeGene Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 49

Employees

  • Stock Symbol
  • 185490

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.22
  • (As of Wednesday Closing)

EyeGene General Information

Description

EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.

Contact Information

Website
www.eyegene.co.kr
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • B-1211, 401 Yangcheon-ro
  • Gangseo-gu
  • Seoul, 07528
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
KRX
Vertical(s)
TMT, Life Sciences, Oncology
Corporate Office
  • B-1211, 401 Yangcheon-ro
  • Gangseo-gu
  • Seoul, 07528
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EyeGene Stock Performance

As of 14-May-2025, EyeGene’s stock price is $2.22. Its current market cap is $60M with 27M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.22 $2.20 $1.68 - $3.45 $60M 27M 72.1K -$0.33

EyeGene Financials Summary

As of 31-Dec-2024, EyeGene has a trailing 12-month revenue of $2.46M.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 26,886 26,886 59,589 39,391
Revenue 2,459 2,459 2,390 4,097
EBITDA (8,298) (8,298) (16,614) (21,322)
Net Income (8,889) (8,889) (16,143) (20,086)
Total Assets 44,336 44,336 60,607 63,648
Total Debt 1,657 1,657 1,669 1,898
Public Fundamental Data provided by Morningstar, Inc. disclaimer

EyeGene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore EyeGene‘s full profile, request access.

Request a free trial

EyeGene Patents

  • 112

    Total Documents Applications and Grants

  • Total Patents Families

  • 43

    Granted

  • 20

    Pending

  • Expiring in next 12 mo

EyeGene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4356933-A1 Composition for delivering modified nucleic acid-containing mrna Pending 07-Sep-2022
AU-2023274159-A1 Composition for in-vivo delivering mrna containing modified nucleotide Pending 07-Sep-2022
AU-2022232410-A1 Composition for in vivo delivery of rna and preparation method therefor Pending 08-Mar-2021
CA-3211256-A1 Composition for in vivo delivery of rna and preparation method therefor Pending 08-Mar-2021
AU-2021433065-A1 Vaccine composition for preventing sars-cov-2 Pending 08-Mar-2021 A61K39/215
To view EyeGene’s complete patent history, request access »

EyeGene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EyeGene Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore EyeGene‘s full profile, request access.

Request a free trial

EyeGene Investments (4)

EyeGene’s most recent deal was a Early Stage VC with MediciBIO. The deal was made on 17-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
MediciBIO 17-Dec-2024 Early Stage VC Biotechnology
NexThera 26-Mar-2024 Early Stage VC Biotechnology
Renhaim Therapeutics 01-Feb-2022 Angel (individual) Biotechnology
Novelty Nobility 30-Jan-2020 Early Stage VC Drug Discovery
To view EyeGene’s complete investments history, request access »

EyeGene ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view EyeGene’s complete esg history, request access »

EyeGene Exits (1)

EyeGene’s most recent exit was on 01-Feb-2022 from Renhaim Therapeutics. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Renhaim Therapeutics 01-Feb-2022 Completed
  • 2 buyers
To view EyeGene’s complete exits history, request access »

EyeGene FAQs

  • When was EyeGene founded?

    EyeGene was founded in 2000.

  • Where is EyeGene headquartered?

    EyeGene is headquartered in Seoul, South Korea.

  • What is the size of EyeGene?

    EyeGene has 49 total employees.

  • What industry is EyeGene in?

    EyeGene’s primary industry is Drug Discovery.

  • Is EyeGene a private or public company?

    EyeGene is a Public company.

  • What is EyeGene’s stock symbol?

    The ticker symbol for EyeGene is 185490.

  • What is the current stock price of EyeGene?

    As of 14-May-2025 the stock price of EyeGene is $2.22.

  • What is the current market cap of EyeGene?

    The current market capitalization of EyeGene is $60M.

  • What is EyeGene’s current revenue?

    The trailing twelve month revenue for EyeGene is $2.46M.

  • What is EyeGene’s annual earnings per share (EPS)?

    EyeGene’s EPS for 12 months was -$0.33.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »